Compare

UL Solutions Inc. vs 20/20 Biolabs, Inc. vs Hypha Labs, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	UL Solutions Inc. ULS	20/20 Biolabs, Inc. AIDX	Hypha Labs, Inc. FUNI
Year ended	2025-12-31	2025-12-31	2025-09-30
Revenue	$3.05B	$2.05M	n/a
Revenue growth (YoY)	+6.4%	+16.7%	n/a
Gross margin	49.5% (computed)	29.6%	n/a
Operating margin	17.1%	-162.9%	n/a
Net margin	10.6%	-182.8%	n/a
Net income	$325.00M	-$3.74M	-$3.10M
EPS (Diluted)	$1.60	-$0.76	-$0.02
Operating cash flow	$600.00M	-$1.92M	-$380.0K
Free cash flow	$403.00M	n/a	-$412.9K
Cash & equivalents	$295.00M	$1.03M	n/a
Total assets	$2.92B	$4.14M	$409.2K
Total liabilities	$1.63B	$4.16M	$2.51M
Shareholders' equity	$1.29B	-$19.2K	-$2.44M
Return on year-end equity	25.1%	n/a	n/a
Shares outstanding	201.03M	5.44M	147.12M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	UL Solutions Inc.	20/20 Biolabs, Inc.	Hypha Labs, Inc.
Latest	$3.05B Ended 2025-12-31	$2.05M Ended 2025-12-31	$2.70M Ended 2022-09-30
1 year earlier	$2.87B Ended 2024-12-31	$1.75M Ended 2024-12-31	$2.50M Ended 2021-09-30
2 years earlier	$2.68B Ended 2023-12-31	n/a	$2.57M Ended 2020-09-30
3 years earlier	$2.52B Ended 2022-12-31	n/a	$2.55M Ended 2019-09-30
4 years earlier	n/a	n/a	$2.84M Ended 2018-09-30